Professor Dr. Her Royal Highness Princess Chulabhorn Mahidol Presides over the Opening Ceremony of the Academic Conference Held in Her Honor
Professor Dr. Her Royal Highness Princess Chulabhorn Mahidol
Presides over the Opening Ceremony of the Academic Conference Held in Her Honor
on the Topic “Frontiers in Biologics Development: Towards a Brighter Future for Thailand”
at the Chulabhorn Research Institute Conference Center, Bangkok
On August 1, 2025 at 09.00 a.m., Professor Dr. Her Royal Highness Princess Chulabhorn Mahidol, President of the Chulabhorn Research Institute (CRI), 
presided over the opening ceremony of the academic conference held in Her Honor on the topic “Frontiers in Biologics Development: Towards a Brighter Future for Thailand” at the Chulabhorn Research Institute Conference Center. The CRI organized the conference to honor Professor Dr. Her Royal Highness Princess Chulabhorn Mahidol who successfully conducted research, development and production of the “trastuzumab” biosimilar for the treatment of cancer patients. The biosimilar was granted a drug registration license by the Food and Drug Administration, Ministry of Public Health, under the name “HERDARA” which was graciously bestowed by Her Royal Highness. This success constitutes a major step in fostering Thailand’s potential to develop drugs without depending on purchases or technology transfer from abroad.
An excerpt of Her Royal Highness’ s address at the opening ceremony is as follows “…Biologics are considered highly safe drugs. They contribute to the hope of treating various present and future diseases …His Majesty King Bhumibol Adulyadej the Great entrusted me, in establishing the Chulabhorn Research Institute, to find ways to enhance potentials in science and technology, aimed to ensure Thailand’s drug security, self-reliance, and research-based drug development…”. Her Royal Highness then attended a lecture in tribute to Herself by Professor Ram Sasisekharan, Massachusetts Institute of Technology (MIT), USA, on the topic “A Tribute to Her Royal Highness Princess Chulabhorn Mahidol: Thailand’s Role in the Global Biologics Era”. Her Royal Highness also attended a special lecture on the topic “From Blackboard to Benchside: The Origin of Biologics in Thailand” by Professor John M. Essigmann, Massachusetts Institute of Technology (MIT), USA, who applauded Her Royal Highness’s accomplishments in laying the foundation of drug development in tandem with domestic personnel development.
This academic conference provided a forum for over 400 leading global experts to share their scientific visions and advancements in drug monitoring systems. It was also honored to welcome international lecturers with major roles in public health and drug regulation system, such as:
- Dr. Janet Woodcock, former Deputy Director, U.S. Food and Drug Administration (U.S. FDA), gave a lecture on the topic “Harmonizing for Health: Regulatory Innovation Across Border” focusing on trends toward developing biologics monitoring system based on science rather than outdated regulations, and strengthening international cooperation to expedite the access to quality drugs in low- and middle- income countries.
- Professor Helen Boucher (M.D.), Dean, School of Medicine, Tufts University, USA, delivered a lecture on “From Resistant to Resilience: AMR as a Case Study for Clinical Innovation”, proposing new approaches to deal with the problems of Antimicrobial Resistance (AMR) while addressing both challenges and opportunities in developing a flexible, data-driven clinical research system.
During the event, an in-depth seminar was also held with participation from experts at Tufts University, National University of Singapore (SingHealth-Duke NUS), Chulalongkorn University, Food and Drug Administration (FDA), Ministry of Public Health, and Chulabhorn Research Institute. Major issues discussed included:
- The future role of biologics in cancer treatment
- Guidelines for access to treatment of rare diseases
- Reform in the production of biologics in the modern age
This important academic forum provided an opportunity for researchers, academics, medical personnel, and experts from leading pharmaceutical institutions both in Thailand and abroad to share knowledge, opinions, and visions related to the development of biologics and modern monitoring system, aimed at enhancing the sustainable future of both Thai and global public health systems.
Public Relations Section
Office of the President
August 1, 2025
Related Posts
Recent Posts
